Chicago, IL - CNS Medical Science Liaison

taylor strategy partners - Chicago, IL3.0

Full-timeEstimated: $56,000 - $75,000 a year
EducationSkills
Overview tsp, a Syneos Health company, is engaged in a direct hire search for Biohaven Pharmaceuticals. Biohaven is currently building a MSL team. As a member of the field-based medical affairs team, this position will function as an extension of the Medical Affairs organization and will be responsible for developing and managing professional relationships with medical thought leaders involved in various stages of product development and medical organizations including treatment centers, established societies and associations.
Responsibilities
Develop & maintain relationships with key scientific centers and leaders within Neurology/Migraine
Scientifically Engage with high priority HCP’s and patient advocacy groups, Pre and Post Launch
Deliver clinical/scientific information to varied audiences with effect.
Support community Affairs and general program mgmt.
Support payer access clinical strategies
Requirements
NP/PA/MSN but PhD, PharmD or MD preferred
2+ years’ experience as an MSL or related neurology research or medical affairs experience
Excellent Communication and Scientific affiliation
CNS experience required, Migraine preferred
Product launch experience preferred
Possess a valid driver's license to drive to assignments, unless otherwise specified
50-60% Travel

Biohaven is a clinical-stage biopharmaceutical company developing a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Biohaven is guided by proven leadership from industry and academic settings with strong support from top-tier biopharma investors.

Biohaven is utilizing an entrepreneurial organizational structure that minimizes hierarchy combined with deep experience in drug development to leverage a range of intellectual property licensed from companies and institutions that include Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.

Since our establishment in 2013, and especially since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist and glutamate modulator platforms. Today, we are ready to achieve a number of new clinical and regulatory milestones, including an NDA filing in 2019 for rimegepant our novel, orally-dosed migraine treatment. We also have a July 2019 PDFUA date for BHV-0223, our novel, sublingual formulation of riluzole for patients with ALS.

Syneos health and its clients are affirmative action/equal opportunity employers (Minorities/Females/Vets/Disabled)